A possible role of Fas-ligand-mediated "reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus

Immunology Letters

Volumn 122, Issue 1, 2009, Pages 12-17

  Telegina, Ekaterina ^a,b   Reshetnyak, Tatiana ^c   Moshnikova, Anna ^b   Proussakova, Olga ^b   Zhukova, Alexandra ^b   Kuznetsova, Alla ^a   Ivanov, Alexei ^a   Paltsev, Michail ^a   Beletsky, Igor ^a,b  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^b INSTITUTE OF THEORETICAL AND EXPERIMENTAL BIOPHYSICS   (Russian Federation)

^c V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

Author keywords

Cytotoxicity; Fas antigen; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

FAS LIGAND;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LYMPHOCYTE; LYMPHOCYTE CULTURE; MAJOR CLINICAL STUDY; MALE; ORGAN INJURY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY;

ADULT; AGED; ANTIGENS, CD95; ARTHRITIS, RHEUMATOID; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MALE; MIDDLE AGED; PROTEIN MULTIMERIZATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SYNOVIAL FLUID;

EID: 59649094980     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2008.10.003     Document Type: Article

References (48)

1. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356 (1992) 314-317
2. Roths J.B., Murphy E.D., and Eicher E.M. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 159 (1984) 1-20
3. Kojima T., Horiuchi T., Nishizaka H., et al. Analysis of fas ligand gene mutation in patients with systemic lupus erythematosus. Arthritis Rheum 43 (2000) 135-139
4. Wu J., Wilson J., He J., Xiang L., Schur P.H., and Mountz J.D. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 98 (1996) 1107-1113
5. Xue C., Lan-Lan W., Bei C., Jie C., and Wei-Hua F. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus. Cell Immunol 239 (2006) 121-128
6. Papadaki H.A., Boumpas D.T., Gibson F.M., Jayne D.R., Axford J.S., Gordon-Smith E.C., et al. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol 115 (2001) 167-174
7. Xu L., Zhang L., Yi Y., Kang H.K., and Datta S.K. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 10 (2004) 411-415
8. Sumida T., Hoa T.T., Asahara H., Hasunuma T., and Nishioka K. T cell receptor of Fas-sensitive T cells in rheumatoid synovium. J Immunol 158 (1997) 1965-1970
9. Zhang J., Bardos T., Mikecz K., Finnegan A., and Glant T.T. Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune murine arthritis. J Immunol 166 (2001) 4981-4986
10. Szodoray P., Jellestad S., Nakken B., Brun J.G., and Jonsson R. Programmed cell death in rheumatoid arthritis peripheral blood T-cell subpopulations determined by laser scanning cytometry. Lab Invest 83 (2003) 1839-1848
11. Nakashima T., Sasaki H., Tsuboi M., et al. Inhibitory effect of glucocorticoid for osteoblast apoptosis induced by activated peripheral blood mononuclear cells. Endocrinology 139 (1998) 2032-2040
12. Kuo P.L. Myricetin inhibits the induction of anti-Fas IgM-, tumor necrosis factor-alpha- and interleukin-1beta-mediated apoptosis by Fas pathway inhibition in human osteoblastic cell line MG-63. Life Sci 77 (2005) 2964-2976
13. Pittoni V., Sorice M., Circella A., et al. Specificity of antinuclear and antiphospholipid antibodies in sera of patients with autoimmune lymphoproliferative disease (ALD). Clin Exp Rheumatol 21 (2003) 377-385
14. Dowling P., Shang G., Raval S., Menonna J., Cook S., and Husar W. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 184 (1996) 1513-1518
15. Nozawa K., Kayagaki N., Tokano Y., Yagita H., Okumura K., and Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40 (1997) 1126-1129
16. Hashimoto H., Tanaka M., Suda T., et al. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 41 (1998) 657-662
17. Ates A., Kinikli G., Turgay M., and Duman M. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin Rheumatol 23 (2004) 421-425
18. Sahin M., Aydintug O., Tunc S.E., Tutkak H., and Naziroglu M. Serum soluble Fas levels in patients with autoimmune rheumatic diseases. Clin Biochem 40 (2007) 6-10
19. Cheng J., Zhou T., Liu C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263 (1994) 1759-1762
20. Silvestris F., Grinello D., Tucci M., Cafforio P., and Dammacco F. Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus 12 (2003) 8-14
21. Desbarats J., Duke R.C., and Newell M.K. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med 4 (1998) 1377-1382
22. Proussakova O.V., Rabaya N.A., Moshnikova A.B., et al. Oligomerization of soluble Fas antigen induces its cytotoxicity. J Biol Chem 278 (2003) 36236-36241
23. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
24. Scott D.L. A simple index to assess disease activity in rheumatoid arthritis. J Rheumatol 20 (1993) 582-584
25. Van der Heijde D.M., van't Hof M.A., van Riel P.L., and Van de Putte L. Disease activity score. Ann Rheum Dis 51 (1992) 140
26. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., and van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 41 (1998) 942-945
27. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
28. Harris E.N., Hughes G.R., and Gharavi A.E. Anti-cardiolipin antibodies and the lupus anticoagulant. Clin Exp Rheumatol 4 (1986) 187-190
29. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 (1999) 1309-1311
30. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., and Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35 (1992) 630-640
31. Borenfreund E., and Puerner J. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 24 (1985) 119-124
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
33. Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., and Struhl K. Short protocols in molecular biology (1992), John Wiley & Sons, New York, NY
34. Kinoshita T., Imamura J., Nagai H., and Shimotohno K. Quantification of gene expression over a wide range by the polymerase chain reaction. Anal Biochem 206 2 (1992) 231-235
35. Christensson M., Pettersson E., Eneslatt K., et al. Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. J Clin Immunol 22 (2002) 220-227
36. Papo T., Parizot C., Ortova M., et al. Apoptosis and expression of soluble Fas mRNA in systemic lupus erythematosus. Lupus 7 (1998) 455-461
37. Catrina A.I., Ulfgren A.K., Lindblad S., Grondal L., and Klareskog L. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 61 (2002) 934-936
38. Papoff G., Hausler P., Eramo A., et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 274 (1999) 38241-38250
39. Vignaux F., Vivier E., Malissen B., Depraetere V., Nagata S., and Golstein P. TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med 181 (1995) 781-786
40. Tak P.P., Klapwijk M.S., Broersen S.F., van de Geest D.A., Overbeek M., and Firestein G.S. Apoptosis and p53 expression in rat adjuvant arthritis. Arthritis Res 2 (2000) 175-178
41. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., and Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270 (1995) 1189
42. Suda T., Okazaki T., Naito Y., et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 154 (1995) 3806-3813
43. Courtney P.A., Crockard A.D., Williamson K., McConnell J., Kennedy R.J., and Bell A.L. Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus 8 (1999) 508-513
44. Alecu M., Coman G., and Alecu S. Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus. Rom J Intern Med 38-39 (2000-2001) 83-88
45. Jodo S., Kobayashi S., Kayagaki N., et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 107 (1997) 89-95
46. Hao J.H., Ye D.Q., Zhang G.Q., et al. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese. Arch Dermatol Res 297 (2006) 329-332
47. Matsuno H., Yudoh K., Nakazawa F., et al. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera. J Rheumatol 29 (2002) 1609-1614
48. Li N.L., Nie H., Yu Q.W., et al. Role of soluble Fas ligand in autoimmune diseases. World J Gastroenterol 10 (2004) 3151-3156